ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
BioSpace

Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
MPR

Combination of Asciminib Plus a TKI Offers Hope of Treatment-Free Remission in CML

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
BioPharma Dive

Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
FiercePharma

Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the Phase 3 DASISION study of ...
ascopubs.org

Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy One hundred sixteen patients in durable CGCR, and ...
Nature

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

A total of 610 (30%) patients had ACAs in addition to t(9;22)(q34;q11.2)/BCR-ABL. Of note, cases with chromosomal changes in Ph-negative cells were not considered as ACAs. Of 610 cases with ACAs, 183 ...
Healio

Nilotinib: a second generation tyrosine kinase inhibitor for the treatment of CML

Please provide your email address to receive an email when new articles are posted on . Chronic myeloid leukemia is a hematologic stem-cell disorder characterized by excessive proliferation and ...
Fred Hutch

Treatment for CML

With today’s medicines, most people with chronic myeloid leukemia (CML) have a normal lifespan and a good quality of life. The key is to get care from CML experts — like the physicians at Fred ...